1-5 of 5
Larry J. Schaaf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy

Donghua Yin, Franzanne Vreeland, Larry J. Schaaf, Robert Millham, Barbara A. Duncan, Amarnath Sharma
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 1000–1009.
https://doi.org/10.1158/1078-0432.CCR-06-1910
Published: 08 February 2007
View articletitled, Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy
Open the PDF for Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy in another window
Journal Articles

Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction

Larry J. Schaaf, Lisa A. Hammond, Stuart J. Tipping, Richard M. Goldberg, Rakesh Goel, John G. Kuhn, Langdon L. Miller, Linda D. Compton, Laura A. Cisar, Gary L. Elfring, Gabriela Gruia, J. Patrick McGovren, Nicoletta Pirotta, Donghua Yin, Amarnath Sharma, Barbara A. Duncan, Mace L. Rothenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (12): 3782–3791.
https://doi.org/10.1158/1078-0432.CCR-05-2152
Published: 15 June 2006
View articletitled, Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction
Open the PDF for Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction in another window
Journal Articles

Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen

Edgardo Rivera, Vicente Valero, Deborah Francis, Aviva G. Asnis, Larry J. Schaaf, Barbara Duncan, Gabriel N. Hortobagyi
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (6): 1943–1948.
https://doi.org/10.1158/1078-0432.CCR-1005-03
Published: 24 March 2004
View articletitled, Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen
Open the PDF for Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen in another window
Journal Articles

Phase I Evaluation of Sequential Topoisomerase Targeting with Irinotecan/Cisplatin Followed by Etoposide in Patients with Advanced Malignancy

Edward J. Licitra, Viral Vyas, Kathy Nelson, Rita Musanti, Stephanie Beers, Cecilia Thomas, Elizabeth Poplin, Sharon Smith, Yong Lin, Larry. J. Schaaf, Joseph Aisner, Murugesan Gounder, Rajeev Rajendra, Ahamed Saleem, Deborah Toppmeyer, Eric H. Rubin
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (5): 1673–1679.
Published: 01 May 2003
View articletitled, Phase I Evaluation of Sequential Topoisomerase Targeting with Irinotecan/Cisplatin Followed by Etoposide in Patients with Advanced Malignancy
Open the PDF for Phase I Evaluation of Sequential Topoisomerase Targeting with Irinotecan/Cisplatin Followed by Etoposide in Patients with Advanced Malignancy in another window
Journal Articles

Phase I Dose-finding and Pharmacokinetic Trial of Irinotecan Hydrochloride (CPT-11) Using a Once-Every-Three-Week Dosing Schedule for Patients with Advanced Solid Tumor Malignancy

Henry C. Pitot, Richard M. Goldberg, Joel M. Reid, Jeff A. Sloan, Pam Atherton Skaff, Charles Erlichman, Joseph Rubin, Patrick A. Burch, Alex A. Adjei, Steven A. Alberts, Larry J. Schaaf, Gary Elfring, Langdon L. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2236–2244.
Published: 01 June 2000
View articletitled, Phase I Dose-finding and Pharmacokinetic Trial of Irinotecan Hydrochloride (CPT-11) Using a Once-Every-Three-Week Dosing Schedule for Patients with Advanced Solid Tumor Malignancy
Open the PDF for Phase I Dose-finding and Pharmacokinetic Trial of Irinotecan Hydrochloride (CPT-11) Using a Once-Every-Three-Week Dosing Schedule for Patients with Advanced Solid Tumor Malignancy in another window